[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health":3,"$f1g3dfuczjg4f":14},{"ok":4,"db":5,"lastOrangeBookRun":6,"lastDrugsFdaRun":9,"lastAlertsRun":12,"stale":13},true,"ok",{"status":5,"startedAt":7,"finishedAt":8,"lastOkAt":8},"2026-10-26T06:44:32.239Z","2026-10-26T06:44:53.640Z",{"status":5,"startedAt":10,"finishedAt":11,"lastOkAt":11},"2026-10-26T06:45:02.648Z","2026-10-26T06:45:13.189Z",null,false,{"tradeName":15,"ingredient":15,"applicant":16,"applicantSlug":17,"applNos":18,"loe":12,"latestLoe":12,"basis":20,"carveOutPossible":13,"openStrengths":21,"headlineStrengths":21,"headlineFallback":13,"approvalsBeforeLoe":22,"products":23,"patents":45,"exclusivities":46,"paragraphIv":47,"catalysts":49},"VENLAFAXINE HYDROCHLORIDE","OSMOTICA PHARM US","osmotica-pharm-us",[19],"022104","none",4,0,[24,33,37,41],{"key":25,"applNo":19,"productNo":26,"dosageForm":27,"route":28,"strength":29,"approvalDate":30,"rld":4,"teCode":31,"type":32,"loe":12,"basis":20,"carveOutPossible":13},"022104-001","001","TABLET, EXTENDED RELEASE","ORAL","EQ 37.5MG BASE","2008-05-20","AB","RX",{"key":34,"applNo":19,"productNo":35,"dosageForm":27,"route":28,"strength":36,"approvalDate":30,"rld":4,"teCode":31,"type":32,"loe":12,"basis":20,"carveOutPossible":13},"022104-002","002","EQ 75MG BASE",{"key":38,"applNo":19,"productNo":39,"dosageForm":27,"route":28,"strength":40,"approvalDate":30,"rld":4,"teCode":31,"type":32,"loe":12,"basis":20,"carveOutPossible":13},"022104-003","003","EQ 150MG BASE",{"key":42,"applNo":19,"productNo":43,"dosageForm":27,"route":28,"strength":44,"approvalDate":30,"rld":4,"teCode":31,"type":32,"loe":12,"basis":20,"carveOutPossible":13},"022104-004","004","EQ 225MG BASE",[],[],{"asOf":12,"firstFiled":12,"entries":48},[],[]]